echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > PacBio and CARE4REVER Collaborate on Rare Disease Research

    PacBio and CARE4REVER Collaborate on Rare Disease Research

    • Last Update: 2022-01-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    This study will assess the impact of high-resolution genomes generated by PacBio technology in studying unsolved rare disease cases

    MENLO PARK, Calif.


    Led by the University of Ottawa-affiliated CEO Institute, Care4Rare has 21 academic locations in Canada and is internationally recognized as a pioneer in genomics and personalized medicine


    "Care4Rare launched the C4R-SOLVE project in 2018 to identify the genetic causes of the most difficult rare diseases and facilitate the introduction of genome-based clinical diagnostic tests into the diagnostic care pathway for all suspected rare diseases in Canada


    More than 7,000 rare diseases are known to affect approximately 1 million Canadians - two-thirds cause severe disability, three-quarters affect children, and more than half cause premature death with little or no treatment method


    PacBio's HiFi long-read whole-genome sequencing (WGS) technology will be used to study rare disease samples that have been sequenced with short-read whole-genome sequencing technology but no genetic variants have been identified


    "Our collaboration with Care4Rare is exciting for all of us who want to help find answers to rare diseases," said Dr.


    The goal of C4R-SOLVE is to more than double Canada's diagnostic capacity for rare diseases, thereby improving patient care and providing new insights into rare diseases through tailored management of their underlying disease


    About Pacific Biosciences

    California-based Pacific Biosciences (NASDAQ:PACB) is providing life scientists with highly accurate long-read sequencing


    PacBio products are for research use only


    About the CHEO Institute

    The Research Centre of the University of Ottawa, Canada coordinates the research activities of the University of Ottawa, Canada, and is affiliated with the University of Ottawa


    forward-looking statements

    This press release may contain "forward-looking statements" within the meaning of the Securities Exchange Act of 1934, as amended, and Section 21E of the US Private Securities Litigation Reform Act of 1995, including Statements relating to the future availability, use, accuracy, advantage, quality or performance of: or the benefit or anticipated benefit of using PacBio products or technologies; the suitability or utility of such products or technologies for particular applications or projects, including Related to Care4Rare Canada and C4R-SOLVE studies; potential increase in variant testing and providing answers for rare disease samples, particularly Care4Rare and C4R-SOLVE studies and rare disease studies in general; development of clinical or diagnostic assays using PacBio technology; and others future events


    contact

    Investor: Todd Friedman 650.


    Media:


    Jennifer Ruff, Director of Communications, CEO Institute jruff@cheo.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.